Skip to content

Elizabeth R. Plimack

Brigham and Women's Hospital

2 papers in the Anchorcite directory, published between 2015 and 2018, cited 10,670 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Nivolumab versus Everolimus in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2015 · 5,913 citations

    BACKGROUND: Nivolumab, a programmed death 1 (PD-1) checkpoint inhibitor, was associated with encouraging overall survival in uncontrolled studies involving previously treated patients with advanced renal-cell carcinoma. This randomized, open-label, phase 3 study compared nivolumab with everolimus in patients with renal-cell…

  2. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell CarcinomaNew England Journal of Medicine · 2018 · 4,757 citations

    BACKGROUND: Nivolumab plus ipilimumab produced objective responses in patients with advanced renal-cell carcinoma in a pilot study. This phase 3 trial compared nivolumab plus ipilimumab with sunitinib for previously untreated clear-cell advanced renal-cell carcinoma. METHODS: We randomly assigned adults in…

Metadata from OpenAlex (CC0).